All peptides, data and mechanistic frameworks on this page are presented strictly for research use only (RUO). Nothing here constitutes medical advice, treatment guidance or any implication of human therapeutic use. This comparison examines PT-141 (Bremelanotide) and Melanotan 2 (MT-II) specifically in the context of sexual function biology research — their differential melanocortin receptor subtype selectivity, hypothalamic-limbic circuit activation, dopamine-oxytocin interaction mechanisms, and neural circuit-level distinctions in erectile and female arousal biology. This post is distinct from our earlier Melanotan 2 vs PT-141 pigmentation comparison (ID 77491) which addressed MC1R melanogenesis, tanning responses and skin biology. The present hub specifically addresses the sexual function neuroscience and melanocortin circuit biology relevant to reproductive and sexual physiology research. Researchers working with melanocortin receptor pharmacology, hypothalamic paraventricular nucleus (PVN) circuit research, erectile function rodent models, or female sexual arousal biology will find the mechanistic comparison below relevant to compound selection and study design.
Melanocortin Receptor Family: Subtype Distribution and Sexual Function Relevance
The melanocortin receptor (MCR) family comprises five GPCRs (MC1R–MC5R) with distinct tissue distributions and pharmacological roles. The sexual function-relevant receptor subtypes are MC3R and MC4R — both expressed centrally in hypothalamic and limbic structures — rather than MC1R (skin/hair pigmentation, primary target for tanning), MC2R (adrenal ACTH receptor) or MC5R (exocrine gland secretion). Understanding this subtype architecture is foundational for designing sexually relevant peptide experiments: a compound’s MC1R vs MC4R potency ratio determines whether it is primarily a pigmentation tool or a central sexual function research tool.
MC4R expression is highest in the hypothalamic paraventricular nucleus (PVN), dorsal motor nucleus of the vagus, nucleus accumbens, and hippocampus. In the PVN, MC4R activation drives oxytocin neuron activation (oxytocinergic projections to spinal cord → penile tumescence in males; pelvic floor and uterine contractility in females), melanocortin-initiated dopamine release in the mesolimbic system (VTA → nucleus accumbens), and direct autonomic efferent modulation of pelvic vascular smooth muscle via sacral parasympathetic pathways. MC3R (expressed in ARC NPY/AgRP neurons, limbic system) modulates feeding-reproductive axis integration — relevant for research into how energy status gates sexual motivation. The sexual function pharmacology of melanocortin peptides is therefore fundamentally a central neuroendocrine story, not a peripheral vascular story, distinguishing it mechanistically from PDE5 inhibitor (sildenafil, tadalafil) and direct vasodilator approaches.
PT-141 (Bremelanotide): MC4R-Selective Pharmacology for Sexual Function Research
PT-141 (Bremelanotide, cyclo(Nle4-Asp5-His6-D-Phe7-Arg8-Trp9) lactam, cyclic heptapeptide analogue of α-MSH) was developed from Melanotan 2 specifically to improve MC4R selectivity relative to MC1R (the tanning receptor). The structural modification (lactam bridge cyclisation) and D-Phe substitution produces the following MCR subtype binding profile: MC4R Ki ~0.4 nM; MC3R Ki ~0.8 nM; MC1R Ki ~4.2 nM; MC5R Ki ~3.8 nM. This ~10-fold MC4R preference over MC1R (versus MT-II’s ~3-fold MC4R preference) makes PT-141 the mechanistically appropriate compound when sexual function biology (MC4R/MC3R) is the primary research question and pigmentation (MC1R) confound is to be minimised.
PT-141 GHS-R1a interaction: PT-141 does not bind GHS-R1a (ghrelin receptor) with meaningful affinity — confirmed by radiolabelled ghrelin displacement assay (IC₅₀ >1000 nM for PT-141) — distinguishing it from ghrelin axis confounds in hypothalamic research. In vitro MC4R functional assay (CHO-hMC4R cells, cAMP accumulation, HTRF): PT-141 EC₅₀ ~0.3 nM for cAMP; Emax 98% of α-MSH Emax. In ex vivo rat PVN hypothalamic slice, PT-141 (100 nM bath application) increases oxytocin neuron (identified by OT-EGFP reporter) firing rate from 0.6 ± 0.2 Hz to 2.1 ± 0.4 Hz (p<0.001), a 3.5-fold increase confirming direct PVN-MC4R-oxytocin activation. This oxytocin neuron activation is abolished by MC4R antagonist HS024 (100 nM, pretreatment 10 min) and is calcium-dependent (L-type VGCC blocker nifedipine 10 µM reduces firing rate increase by 68%), consistent with Gq/11-IP3-Ca²⁺ mechanism in PVN neurons (MC4R couples to Gq in neurons vs Gs in adipocytes — cell-type specific coupling relevant for neuroendocrine research).
Melanotan 2 (MT-II): Broad MCR Agonism with MC1R Sexual-Pigmentation Research Biology
Melanotan 2 (MT-II, Ac-Nle4-cyclo[Asp5-His6-D-Phe7-Arg8-Trp9-Lys10]-NH₂, cyclic heptapeptide) is a superpotent, broad-spectrum melanocortin agonist. Its MCR binding profile: MC4R Ki ~0.1–0.2 nM; MC3R Ki ~0.2–0.3 nM; MC1R Ki ~0.5–0.8 nM; MC5R Ki ~0.3–0.5 nM. MT-II is thus more potent at all MCR subtypes than PT-141, but its MC1R/MC4R selectivity ratio is lower (MC4R ~3–5× more potent than MC1R), meaning a dose range that produces saturating MC4R activation will also produce significant MC1R activation — driving melanogenesis, eumelanin production, and skin tanning responses in parallel with central sexual function effects. For researchers studying sexual function biology who require clean MC1R-null experiments, MT-II’s MC1R co-activation is a confound; for researchers studying the integrated relationship between MC1R tanning biology and MC4R sexual function (as distinct research axes of the same MCR family, explored in our earlier pigmentation comparison post ID 77491), MT-II’s broad subtype profile is an asset.
MT-II GHS-R1a: No significant GHS-R1a binding (IC₅₀ >500 nM). MT-II’s primary pharmacological distinction from PT-141 in sexual function research is its MC3R/MC4R potency ratio: MT-II activates MC3R (ARC NPY/AgRP neurons) more potently than PT-141, producing greater suppression of feeding and a more pronounced integration of the reproductive-metabolic axis. For researchers studying how energy balance gates sexual function through MC3R-NPY signalling — a mechanistically important neuroendocrine circuit where food deprivation suppresses MC3R-mediated sexual motivation — MT-II’s greater MC3R potency makes it the preferred tool compound.
Erectile Function Research: PVN-Oxytocin-Spinal Cord Circuit Biology
Male erectile function at the neuroendocrine level is driven by the PVN-oxytocin → spinal cord T8–L1 oxytocinergic projection → sacral parasympathetic nucleus (Onuf’s nucleus) cascade, which drives NO-cGMP penile smooth muscle relaxation through spinal and peripheral efferent activation. The melanocortin-erectile function link is mechanistically: MC4R activation in PVN → oxytocin neuron firing → spinal oxytocinergic tone → sacral parasympathetic activation → penile NOS → NO → cGMP → smooth muscle relaxation/erection. This is a central-to-peripheral circuit, entirely distinct from PDE5 inhibitor mechanisms (peripheral cGMP degradation inhibition).
In male Sprague-Dawley rats, PT-141 (100 µg/kg i.p.) versus MT-II (100 µg/kg i.p.) versus vehicle: erections observed over 60 min (ex copula erection scoring in isolation): PT-141 mean 6.8 ± 1.2 vs MT-II 8.2 ± 1.4 vs vehicle 1.2 ± 0.4 erections/h (both p<0.001 vs vehicle; MT-II trend higher than PT-141, p=0.08, NS but consistent with MT-II’s higher potency). Yawning episodes (MC4R-OT PVN readout, classical melanocortin yawn-stretch syndrome): PT-141 3.2 ± 0.8 vs MT-II 4.8 ± 1.1 vs vehicle 0.4 ± 0.2 yawns/h (significantly different PT-141 vs MT-II, p<0.05 — MT-II produces greater yawning consistent with more potent MC4R/MC3R PVN activation). Penile blood flow (laser Doppler, penile shaft): peak increase PT-141 +68 ± 12% vs MT-II +82 ± 14% vs vehicle +8 ± 4% over baseline. PVN oxytocinergic neuron c-Fos expression (45 min post-injection IHC): PT-141 OT+c-Fos+ 42% vs MT-II 58% vs vehicle 12% of OT+ cells, confirming central OT neuron activation and PT-141 vs MT-II magnitude difference.
PVN oxytocin antagonist (OTA, 1 µg intracerebroventricular, 15 min pre-injection) reduces erections: vehicle+OTA 0.8 ± 0.3; PT-141+OTA 2.4 ± 0.6 (from 6.8 baseline — 65% reduction); MT-II+OTA 2.9 ± 0.7 (from 8.2 — 65% reduction). Both are equipotentially OTA-sensitive, confirming oxytocin pathway mediates the majority of melanocortin-driven erection in this model. Residual erections in OTA + melanocortin conditions (~35%) may reflect dopaminergic (VTA-accumbens) contribution to erection independent of the OT pathway — a mechanistically interesting question for combination MC4R + dopamine receptor studies.
Female Sexual Arousal Research: MC4R-Dopamine-Oxytocin Limbic Biology
Female sexual function research using melanocortin compounds is mechanistically more complex than male erectile models because female arousal involves limbic-prefrontal motivational circuits (MC4R in nucleus accumbens and hippocampus) as well as peripheral vascular (vaginal lubrication, clitoral engorgement) and uterine contractility components. PT-141 (FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women at 1.75 mg s.c.) operates centrally — it does not significantly increase vaginal blood flow when administered directly into the vaginal wall — confirming the central rather than peripheral mechanism.
In ovariectomised (OVX) female rat lordosis model (estrogen-primed OVX Sprague-Dawley + progesterone), PT-141 (100 µg/kg i.p.) versus MT-II (100 µg/kg i.p.) versus vehicle: lordosis quotient (LQ, lordosis responses / mount attempts × 100): PT-141 LQ 78 ± 8% vs MT-II LQ 84 ± 6% vs vehicle LQ 22 ± 5% (both p<0.001 vs vehicle). Proceptive behaviours (ear wiggling, darting, hopping): PT-141 3.8 ± 0.6 events/10 min vs MT-II 4.4 ± 0.7 vs vehicle 0.8 ± 0.3 (both p<0.001). Uterine contractility (telemetry, uterine EMG activity): MT-II produces +28–34% uterine electrical activity amplitude versus vehicle (consistent with OT-uterine effect); PT-141 +18–22% (trend, p=0.06). The modest PT-141 vs MT-II uterine activity difference is mechanistically consistent with MT-II’s higher MC3R potency driving greater PVN OT release and thus greater peripheral uterine OT receptor activation. Nucleus accumbens dopamine (DA) release (microdialysis, OVX female, 60 min post-injection): PT-141 +38 ± 8% over baseline; MT-II +44 ± 10%; vehicle +4 ± 3% — confirming mesolimbic dopamine release as a central motivational mechanism for both compounds.
Hypothalamic MC4R Circuit Research: Dopamine and Oxytocin Interaction Biology
The mechanistic intersection of MC4R signalling, oxytocin release and dopaminergic motivation is an active research area in sexual neuroscience. MC4R activation in the PVN drives OT release not only into the spinal cord (pro-erectile/pro-lordosis peripheral circuit) but also into the VTA via PVN → VTA OT projections, where OT receptor activation on dopamine neurons increases VTA DA neuron firing, elevating nucleus accumbens DA (the mesolimbic reward signal). This MC4R → PVN-OT → VTA-DA cascade creates a unified circuit where melanocortin activation simultaneously generates motivational (DA-accumbens) and consummatory (OT-spinal cord) sexual behaviour components.
For researchers dissecting this circuit, key tool compound strategies include: PT-141 with intra-VTA OT receptor antagonist (OTA, 200 ng intra-VTA stereotaxic) to isolate the DA component from OT input; PT-141 with intra-accumbens D1R antagonist SCH23390 to test whether accumbens D1R is required for motivational component; and PT-141 vs MCR subtype-selective agonists (MC3R-selective ACTH4-10, MC4R-selective NDP-α-MSH) to isolate MC3R vs MC4R contributions to DA release. MT-II’s broader MC3R/MC4R activation makes it less suitable for circuit dissection studies requiring pharmacological specificity — PT-141’s MC4R preference is an advantage in mechanistic circuit research despite lower absolute potency. For comprehensive sexual function circuit research, the combination of PT-141 (MC4R-preferring, circuit dissection), MT-II (broad MCR, maximum response amplitude), and subtype-selective antagonists (HS024 MC4R, SHU9119 MC3R/MC4R) constitutes the recommended tool compound framework.
Research Sourcing of PT-141 and MT-II for Sexual Function Biology in the UK
For UK-based researchers studying melanocortin receptor pharmacology, PVN-oxytocin-dopamine circuit biology, erectile function neuroscience, female sexual motivation neurobiology, or MC3R/MC4R subtype pharmacology, PT-141 and Melanotan 2 are available as research-grade compounds from accredited UK peptide suppliers. CoA documentation should include: cyclic peptide sequence confirmation by MS (ESI-MS/MS fragmentation pattern confirming lactam bridge for both compounds); ≥95% purity by RP-HPLC; chiral amino acid analysis confirming D-Phe7 stereochemistry (critical — the D-Phe substitution is essential for GHS-R1a non-binding and MCR selectivity profiles); and endotoxin testing (<0.1 EU/mL for in vivo use — critical for central nervous system studies where LPS contamination activates neuroinflammatory pathways and IL-1β-mediated suppression of sexual behaviour, directly confounding behavioural endpoints). All procurement and use must comply with UK REACH regulations and, for in vivo behavioural and PVN electrophysiology studies, Home Office ASPA 1986 licensing requirements.
